13 results about "Vaginal epithelial cell" patented technology

The application discloses a human vagina micro-ecological in-vitro model and a construction method and application thereof, and relates to the technical field of medicines.The application discloses a human vagina micro-ecological in-vitro model and a construction method and application thereof.Firstly, a mixed cell group of the vaginal epithelium containing a complete cell lineage and capable of long-term subculture is successfully established, a technical bottleneck that primary vaginal epithelial cells are difficult to expand is solved, and ideal seed cells are provided for model construction.Secondly, a highly-bionic vaginal mucosa model having a tight connection structure, rich layers and an orderly arrangement is constructed, and the physiological barrier and immune regulation functions of the vaginal mucosa are truly simulated.Finally, by introducing lactobacillus symbiosis and confirming the response to estrogen, a multi-element in-vitro research model integrating the anatomical structure of the vagina, resident flora, local immunity and endocrine regulation is constructed, and a reliable technical platform is provided for in-depth exploration of the mechanism of vaginal micro-ecological disorder and efficient screening of related drugs.

The invention discloses a composition of type III collagen and beta-glucan and application of the composition in repairing vaginal mucosa injury, and belongs to the technical field of biological medicine, and the composition comprises the following effective components: type III collagen with the concentration of 0.3-1.8 mg / mL and beta-glucan with the mass concentration of 0.1-0.8%. The collagen III provides structural support required by tissue repair, the beta-glucan improves inflammation microenvironment, regulates immune response and jointly promotes proliferation and migration of damaged vaginal epithelial cells, the cell proliferation rate and the scratch healing rate are far higher than those of a group using any component independently, and rapid repair of mucosal lesions can be achieved.

The present application relates to the technical field of microorganisms, in particular to a lactobacillus crispatus Lcr5-6 and application thereof, the lactobacillus crispatus Lcr5-6 is preserved in the China General Microbiological Culture Collection Center, and the preservation number is CGMCC No.38486;The adhesion rate of the lactobacillus crispatus Lcr5-6 to Hela cells is as high as 61.11%, which is significantly higher than that of the control strain lactobacillus delbrueckii DM8909 (12.13%), has excellent vaginal epithelial cell adhesion and colonization ability, and can be long-term colonization in the vagina to play a probiotic role.

The invention discloses a sheep oestrus monitoring system based on cell image morphology recognition, and the system is characterized in that the system comprises a sample collection module (100) which obtains a sheep vagina epithelial cell sample and carries out the dyeing of the cell sample; the microscopic imaging module (200) performs optical amplification on the dyed cell sample to generate a cell morphology image; the image processing module (300) extracts cell edge contours and quantifies morphological irregular features; and the intelligent analysis module (400) judges the estrus state of the sheep by comprehensively analyzing the nuclear off-center proportion and the form irregularity index. The sheep oestrus monitoring system based on cell image morphological recognition has the advantages that high-sensitivity capture of biological markers in the early oestrus stage is achieved by fusing dual morphological criteria of cell nucleus spatial displacement analysis and contour geometric distortion detection, and the timeliness and accuracy of reproduction regulation and control are remarkably improved.

The present invention addresses the problem of providing a novel therapeutic agent that is effective against diseases involving stratified squamous epithelial cells such as dry eye syndrome. The present invention is an agent for promoting normal differentiation / maturation of stratified squamous epithelial cells, which comprises a secretion of mesenchymal stem cells. It is preferable that the secretions not include animal serum, that the mesenchymal stem cells be adipose-derived mesenchymal stem cells, umbilical cord-derived mesenchymal stem cells, or bone marrow-derived mesenchymal stem cells, and that the stratified squamous epithelial cells be at least one selected from the group consisting of corneal epithelial cells, conjunctival epithelial cells, epidermal keratinocytes, oral epithelial cells, epiglottic epithelial cells, esophageal epithelial cells, vaginal epithelial cells, vocal fold epithelial cells, nasal epithelial cells, and nasal vestibular epithelial cells.

The invention discloses a condom added with sophocarpidine hyaluronic acid lubricating liquid and a preparation method of the condom, and belongs to the technical field of condom production. The core of the method is that after matrine is dissolved, the matrine is added into hyaluronic acid lubricating liquid for the condoms, the hyaluronic acid lubricating liquid containing the matrine is prepared through stirring and mixing, the concentration of the matrine in the hyaluronic acid lubricating liquid is 7.7-25.0 mg / g, when the condoms are subjected to inner packaging, the matrine-containing lubricating agent is added into the condoms, and when the condoms are subjected to inner packaging, the matrine-containing lubricating agent is added into the condoms. And preparing the condom added with the sophocarpidine-containing hyaluronic acid lubricating liquid. According to the condom, inflammation generated after vaginal epithelial cells are stimulated by bacterial structural components is improved through matrine, and the common pathogenic bacteria such as staphylococcus aureus, escherichia coli, enterococcus faecalis and streptococcus agalactiae of vaginitis are inhibited in the using process; and the up-regulation level of NF-kB phosphorylation generated after lipopolysaccharide and peptidoglycan stimulate vaginal epithelial cells is relieved.

This invention belongs to the field of biomedicine and discloses the application of HMOX1 inhibitors in the preparation of drugs for treating senile vaginitis. This invention is the first to discover that the content of the metabolite MESV1 (Guggulsterone) is significantly elevated in the vaginal secretions of patients with senile vaginitis. MESV1 induces ferroptosis in vaginal epithelial cells by upregulating HMOX1 protein expression, thereby driving the disease. Based on this, this invention proposes a novel therapeutic strategy targeting HMOX1. The inhibitors include shRNAs targeting HMOX1 (such as SEQ ID NO: 1-3), which can be prepared into vaginal gels, creams, and other dosage forms. Simultaneously, MESV1 can also be used to prepare auxiliary diagnostic kits. This invention provides a novel target and precise treatment approach for non-hormonal treatment of senile vaginitis.

This application discloses an in vitro reconstructed vaginal mucosa model, its construction method, and its application. The construction method includes an improved culture medium: HVU medium is added to immortalized vaginal epithelial cell line VK2 / E6E7, which is then seeded into Transwell chambers and cultured. The HVU medium on the surface of the culture in the Transwell chambers is aspirated, and the Transwell chambers are raised to the air-liquid interface for air-liquid surface culture. The culture medium is then replaced with HVA medium to obtain the vaginal mucosa model. This method improves the stability of cells during in vitro culture and constructs an in vitro reconstructed vaginal mucosa model with a tissue structure highly similar to human vaginal mucosa (possessing a complete stratified squamous epithelial structure and normal intercellular connections), thereby enhancing the model's physiological functional simulation.

The invention discloses lactobacillus gasseri WT002 which is preserved in the general microbiological center of the China Committee for Culture Collection of Microorganisms on February 18, 2025, and the preservation number of the lactobacillus gasseri WT002 is CGMCC No.33552. The lactobacillus gasseri WT002 is named as Lactobacillus gasseri WT002. The lactobacillus gasseri WT002 can inhibit the growth of various vaginal pathogenic bacteria, has strong vaginal epithelial cell and cervical cancer cell adhesion ability, can be used for preventing and / or relieving and / or treating genital tract diseases, and further can be used for preparing medicines, hygienic products and the like.

The invention discloses lactobacillus crispatus WT001 which is preserved in the general microbiological center of the China Committee for Culture Collection of Microorganisms on February 18, 2025, and the preservation number of the lactobacillus crispatus WT001 is CGMCC No.33551. The lactobacillus crispatus WT001 has the advantages that the lactobacillus crispatus WT001 is preserved in the China General Microbiological Culture Collection Center on February 18, 2025; the lactobacillus crispatus WT001 can inhibit the growth of various vaginal pathogenic bacteria, has strong vaginal epithelial cell and cervical cancer cell adhesion ability, can be used for preventing and / or relieving and / or treating genital tract diseases, and further can be used for preparing medicines, hygienic products and the like.

The application discloses a lactobacillus crispatus for relieving various vaginitis based on host immune regulation, and belongs to the technical field of microorganisms. The application provides a lactobacillus crispatus CCFM1298, which is preserved in the Guangdong Microbial Culture Collection Center on December 9, 2022, and has a preservation number of GDMCC No: 62275. The lactobacillus crispatus CCFM1298 targets the vaginal immune system, down-regulates pro-inflammatory factors IL-1beta and TNF-alpha, and up-regulates the expression of anti-inflammatory factor IL-10, is suitable for relieving various vaginal inflammations and pathological improvement, and significantly reduces the shedding of vaginal epithelial cells. The lactobacillus crispatus is derived from the vagina of a healthy female, is a probiotic strain suitable for human vaginal application, helps to relieve and improve various vaginal infections of females, and has a good application prospect.

The application discloses a kind of based on cell image morphological identification's sheep estrus monitoring system, including its features in, including sample acquisition module (100) obtains sheep vaginal epithelial cell sample and carries out dyeing treatment to cell sample;Microscopic imaging module (200) carries out optical amplification to the cell sample after dyeing and generates cell morphology image;Image processing module (300) extracts cell edge contour and quantifies morphological irregular feature;Intelligent analysis module (400) is determined by the comprehensive analysis to nuclear deviation center proportion and morphological irregular index, judges sheep estrus state.The application has beneficial effect for proposing a kind of based on cell image morphological identification's sheep estrus monitoring system, by fusing the double morphological criterion of nuclear space displacement analysis and contour geometric distortion detection, realizes the high sensitivity capture to early estrus biological marker, significantly improves the timeliness and precision of reproduction control.

This invention discloses a strain of *Lactobacillus johnsonii* and its metabiotic that simultaneously improves vaginal mucosal damage and inhibits vaginal inflammation, belonging to the field of microbial technology. The *Lactobacillus johnsonii* strain of this invention was isolated from vaginal secretions of healthy women. It has the effects of improving vaginal mucosal damage and inhibiting vaginal inflammation, specifically manifested in: promoting the migration and repair of vaginal epithelial cells; reducing the content of soluble cadherin E in the vaginal mucosa of mice and increasing the expression of vaginal tight junction protein OCLN; reducing the shedding of vaginal mucosal epithelial cells; reducing the secretion of MPO and IL-1β in mice with vaginitis; and (6) improving the pathological characteristics of the vagina in mice. Therefore, this *Lactobacillus johnsonii* has great application potential in products that improve vaginal mucosal damage and inhibit vaginal inflammation.